Statins linked to 15% lower glaucoma risk and reduced need for surgery

A large study examining two decades of medical records has found that people taking statins—drugs prescribed primarily to manage cholesterol—show a substantially lower risk of developing glaucoma and, if they do develop the disease, are far less likely to need surgery or escalating treatments to control it.

The research, published in the British Journal of Ophthalmology, compared more than 210,000 statin users with an equal number of people who had never taken the drugs, all drawn from a database covering 165 million individuals worldwide. Both groups had documented eye care visits, allowing researchers to track glaucoma diagnoses over time. The statin users showed a 15% lower risk of developing open-angle glaucoma, the most common form of the disease. At the five-year mark, 2.3% of statin users had been diagnosed with glaucoma compared to 2.6% of those who had never taken the medication.

Glaucoma damages the optic nerve irreversibly and stands as a leading cause of blindness worldwide. The disease often progresses silently, with patients unaware of vision loss until significant damage has occurred. Current treatment relies on eye drops, laser procedures, or surgery to lower the pressure inside the eye—the primary driver of nerve damage. The fact that statin users required these interventions less frequently suggests the drugs may offer protection beyond their well-known cholesterol-lowering effects.

When researchers examined a separate group of more than 30,000 people who already had glaucoma and were taking statins, compared against nearly 250,000 glaucoma patients not on statins, the protective pattern intensified. Over five years, statin users faced a 36% lower risk of needing incisional glaucoma surgery—the most invasive option—and a 55% reduced risk of minimally invasive glaucoma surgery, a keyhole procedure that lowers eye pressure. The reduction extended to laser treatment, with statin users showing a 60% lower risk of needing selective laser trabeculoplasty. Even the need for prescription eye drops, the first-line treatment most patients try, dropped by 12% among statin users. These associations held up at the ten-year follow-up as well.

Statins have long been suspected of having neuroprotective properties—the ability to slow or prevent the death of nerve cells. How this might work in glaucoma remains poorly understood, but the mechanism likely involves protecting the optic nerve from the damage caused by elevated eye pressure. The drugs are not currently prescribed for glaucoma prevention or treatment, and this study does not prove they cause the observed benefits.

The research carries important limitations. It is observational, meaning researchers tracked what happened to people who chose to take statins rather than randomly assigning some to take them and others not to. Without access to individual patient records, researchers could not determine whether people who needed surgery had more severe disease or simply were not using their eye drops consistently. They also lacked detailed measurements of eye pressure, which would clarify whether statins directly lowered pressure or worked through another pathway.

The authors acknowledge these constraints but argue their findings add weight to a growing body of evidence suggesting statins may protect nerve tissue. They call for randomized controlled trials—the gold standard in medical research—to determine whether statins could one day become part of glaucoma prevention or treatment strategy. Until then, the study offers an intriguing signal: a drug millions of people already take for their hearts may also be protecting their sight.